Prospective RCT on Post Prostatectomy Urine Leak
Primary Purpose
Prostate Cancer, Urinary Incontinence
Status
Unknown status
Phase
Phase 3
Locations
France
Study Type
Interventional
Intervention
Duloxetine
Pelvic Floor Muscle Training
Sponsored by
About this trial
This is an interventional treatment trial for Prostate Cancer
Eligibility Criteria
Inclusion Criteria:
1. All consecutive patients undergoing Robotic Assisted Radical Prostatectomy for clinically organ confined prostate cancer
Exclusion Criteria:
- Prior urethral, bladder or prostate surgery
- Pelvic radiotherapy.
- Overactive bladder
- Known neurological disease associated to LUTS
- Hepatic impairment with hepatic insufficiency.
- Severe renal impairment (creatinine clearance < 30ml/min)
- Hypersensitivity to duloxetine
- Uncontrolled hypertension
Narrow angle glaucoma
Post-operative criteria:
- Post-void residual urine volume > 100ml measured 15 days after the RARP
Sites / Locations
- Institut Mutualiste montsourisRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
No Intervention
Active Comparator
Active Comparator
Active Comparator
Arm Label
Control
Duloxetine
Duloxetine + PMFT
Pelvic Floor Muscle Training
Arm Description
Keigel's exercise
Duloxetine 60mg for 3 months
Duloxetine 60mg for 3 months PMFT weekly for 3 months
PMFT weekly for 3 months
Outcomes
Primary Outcome Measures
Urinary continence proportion
Proportion of patient achieving continence at 6 months
Secondary Outcome Measures
Urinary continence time
time to achieve continence
Urinary quality of life
Quality of life tested in relation to incontinence using questionnaire at 6 months
Full Information
NCT ID
NCT02367404
First Posted
February 13, 2015
Last Updated
September 12, 2016
Sponsor
Institut Mutualiste Montsouris
1. Study Identification
Unique Protocol Identification Number
NCT02367404
Brief Title
Prospective RCT on Post Prostatectomy Urine Leak
Official Title
A Prospective Randomized Controlled Study Comparing the Efficacy of Pelvic Floor Muscle Training and Oral Duloxetine in the Recovery of Continence After Robotic Assisted Radical Prostatectomy
Study Type
Interventional
2. Study Status
Record Verification Date
September 2016
Overall Recruitment Status
Unknown status
Study Start Date
May 2015 (undefined)
Primary Completion Date
February 2017 (Anticipated)
Study Completion Date
June 2017 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Institut Mutualiste Montsouris
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Objectives:
Primary: Comparison of proportion of patient achieving continence between the four arms at 6 months.
Secondary:
Comparison of time to achieve continence between the four arms.
Comparison of urinary symptoms and quality of life improvement between the four arms.
Assessment of adverse events in Duloxetine arms.
Primary outcome/ time frame: Proportion of patient achieving continence at 6 months. Continence is defined as "using no pad"or "only security pad".
Secondary outcome:
time to achieve continence
Quality of life tested in relation to incontinence according to Visual Analog Scale (VAS) and King's Health Questionnaire (KQH).
Urinary symptoms measured with International Prostate Symptom Score (IPSS).
No. of subjects entered: 300 patients informed and included, 240 patients will be randomized.
Statistical methods
Proportion of patients who achieve continence and time to achieve continence will be compared between the four arms.
Comparison of quality of life outcomes between the four arms
Comparison of clinical variables that can affect the primary/secondary outcome - univariate and multivariate analysis (ITT).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Prostate Cancer, Urinary Incontinence
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
240 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Control
Arm Type
No Intervention
Arm Description
Keigel's exercise
Arm Title
Duloxetine
Arm Type
Active Comparator
Arm Description
Duloxetine 60mg for 3 months
Arm Title
Duloxetine + PMFT
Arm Type
Active Comparator
Arm Description
Duloxetine 60mg for 3 months PMFT weekly for 3 months
Arm Title
Pelvic Floor Muscle Training
Arm Type
Active Comparator
Arm Description
PMFT weekly for 3 months
Intervention Type
Drug
Intervention Name(s)
Duloxetine
Other Intervention Name(s)
Cymbalta
Intervention Description
Duloxetine 60mg OD for 3 months
Intervention Type
Behavioral
Intervention Name(s)
Pelvic Floor Muscle Training
Other Intervention Name(s)
Pelvic Physiotherqpy
Intervention Description
PMFT weekly for 3 months
Primary Outcome Measure Information:
Title
Urinary continence proportion
Description
Proportion of patient achieving continence at 6 months
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Urinary continence time
Description
time to achieve continence
Time Frame
6 months
Title
Urinary quality of life
Description
Quality of life tested in relation to incontinence using questionnaire at 6 months
Time Frame
6 months
10. Eligibility
Sex
Male
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
1. All consecutive patients undergoing Robotic Assisted Radical Prostatectomy for clinically organ confined prostate cancer
Exclusion Criteria:
Prior urethral, bladder or prostate surgery
Pelvic radiotherapy.
Overactive bladder
Known neurological disease associated to LUTS
Hepatic impairment with hepatic insufficiency.
Severe renal impairment (creatinine clearance < 30ml/min)
Hypersensitivity to duloxetine
Uncontrolled hypertension
Narrow angle glaucoma
Post-operative criteria:
Post-void residual urine volume > 100ml measured 15 days after the RARP
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Rafael Sanchez-Salas, MD
Phone
0156616617
Email
rafael.sanchez-salas@imm.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Rafael Sanchez-Salas, MD
Organizational Affiliation
Institute Mutualiste Montsouris
Official's Role
Principal Investigator
Facility Information:
Facility Name
Institut Mutualiste montsouris
City
Paris
ZIP/Postal Code
75014
Country
France
Individual Site Status
Recruiting
12. IPD Sharing Statement
Learn more about this trial
Prospective RCT on Post Prostatectomy Urine Leak
We'll reach out to this number within 24 hrs